RANO Criteria for Brain Metastases

Last edited and medically reviewed by on

The RANO Working Group continuously adapts radiological criteria to measure treatment effects in various brain tumors and make them comparable under study conditions1. The following table of RANO criteria applies to brain metastases.

Criterion Complete Response Partial Response Stable Disease Progressive Disease
Target lesion None Reduction of ≥ 30% in the sum of the longest dimensions compared with baseline. Reduction of < 30% relative to baseline but < 20% increase in the sum of the longest dimensions relative to the nadir. Increase of ≥ 20% in the sum of the longest dimensions relative to the nadir
Non-target lesion None Stable or improved stable or improved progressive
Corticosteroids None Stable or ↓ Stable or ↓ N/A
Clinical status Stable or ↑ Stable or ↑ Stable or ↑ Deterioration
Required for response All criteria All criteria All criteria One of the criteria

RANO criteria for brain metastases.
Illustration of the RANO criteria for brain metastases from the 2017 publication.

References

    1. Wen, Patrick Y., et al. "Response assessment in neuro-oncology clinical trials." Journal of Clinical Oncology 35.21 (2017): 2439. ↩ ↩

    Editorial transparency

    Authorship & revisions

    Who created and updated this article, and which changes are documented.

    Article created by
    Last edited:
    on
    Revision history
    5 edits · 1 contributor
    Author list:
    Show revision history 5 entries

    5 edits by 1 author

    Edit · Alaric Steinmetz · (+1 −1)

    No content change recorded

    Edit · Alaric Steinmetz ·

    No content change recorded

    Edit · Alaric Steinmetz · (+5 −5)
    • Text changed: “| Criterion | Complete Response | Partial Response | Stable Disease | Progressive Disease | | --------- | ----------------- | ----------------- | -------------- | ------------------- | | Target lesion | None | Reduction of ≥ 30% in the sum of the longest diameters compared with baseline. | Reduction of < 30% relative to baseline but < 20% increase in the sum of the longest diameters relative to the [nadir](\/lexikon\/nadir). | Increase of ≥ 20% in the sum of the longest diameters relative to the nadir | | Non-target lesion | None | Stable or improved | Stable or improved | Progressive | | Corticosteroids | None | Stable or ↓ | Stable or ↓ | N\/A | | Clinical status | Stable or ↑ | Stable or ↑ | Stable or ↑ | Deterioration | | Required for response | All criteria | All criteria | All criteria | One of the criteria |”“| Criterion | Complete Response | Partial Response | Stable Disease | Progressive Disease | | --------- | ----------------- |-------------------|----------------|----------| | Target lesion | None | Reduction of ≥ 30% in the sum of the longest dimensions compared with baseline. | Reduction of < 30% relative to baseline but < 20% increase in the sum of the longest dimensions relative to the [nadir](\/lexikon\/nadir). | Increase of ≥ 20% in the sum of the longest dimensions relative to the nadir | | Non-target lesion | None | Stable or improved | stable or improved | progressive | | Corticosteroids | None | Stable or ↓ | Stable or ↓ | N\/A | | Clinical status | Stable or ↑ | Stable or ↑ | Stable or ↑ | Deterioration | | Required for response | All criteria | All criteria | All criteria | One of the criteria |”
    Edit · Alaric Steinmetz ·

    No content change recorded

    Article created on · Alaric Steinmetz

    Image viewer

    Image

    Open original